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Abstract
A comprehensive totally aqueous phase synthesis of nickel-nitrilotriacetate
(Ni-NTA) modified superparamagnetic Fe3O4 nanoparticles is presented.
The Fe3O4-NTA–Ni nanoparticles are able to perform efficient and specific
purification of 6-His tagged proteins from crude cell lysates, as evidenced by
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
and Western blot analysis. The average binding capacity, as demonstrated by
streptopain (MW 42 kDa), is 0.23 mg/mg (protein/Fe3O4-NTA–Ni).
Considering the high affinity and specificity of the binding between
hexahistidine motif and Ni-NTA, Ni-NTA modified nanoparticles could act
as a module to carry 6-His tagged proteins on the particle surface with
molecular orientation control, since only the 6-His domain could be attached.
These modularly designed functional nanoparticles enhance cancer cell
targeting, as supported by the in vitro receptor mediated targeting assay using
RGD-4C-6-His fusion peptide. The nanoparticles show no significant
hemolysis for human blood and could be investigated further for their
in vivo functional imaging applications.
(Some figures in this article are in colour only in the electronic version)
1. Introduction
Nanoparticles have recently been investigated extensively for
their potential biomedical applications in both diagnostics
and therapeutics due to their distinct physical and chemical
properties compared to the bulk status. In most applications,
cross-linkage of the proteins onto the nanoparticles has
6 Authors to whom any correspondence should be addressed.
utilized traditional chemical cross-linkers, which may result in
unpredictable biomolecule orientation on the particle surfaces.
Traditional chemical cross-linking strategies also fail to form
a homogenous monolayer of ligands in most cases and
thus increase the overall diameter and asymmetry of the
nanoparticles. All these disadvantages lead to compromised
binding and targeting efficiency.
Various metal ions have been identified to interact with
a lot of different proteins [1–3]. Through a comprehensive
0957-4484/06/164174+09$30.00 © 2006 IOP Publishing Ltd Printed in the UK 4174
Aqueous nickel-nitrilotriacetate modified Fe3O4–NH+3 nanoparticles
Scheme 1. Simplified process for rapid adsorption and elution of 6-His tagged proteins from bacteria or cells by Fe3O4–NTA–Ni
nanoparticles. The nanoparticles are mixed with bacteria lysate and subject to further magnetic force separation and washing to remove the
remnants and the non-specific bindings. The target proteins are recovered by elution buffer containing imidazole as the competitor and the
nanoparticles could be reused after re-activation. The specific affinity between 6-His tag and Ni-NTA on the nanoparticles also serves as a
module for rapid orientation controlled bioconjugation for 6-His tagged functional peptides. As a demonstration, we have self-assembled
RGD-4C-6-His fusion peptide on the Ni-NTA-nanoparticles which presents integrin expression specific targeting to the oral cancer cells
compared to the normal oral keratinocytes.
coordination, electron-donor atoms such as S, O or N in
the amino acid residues may interact with metal ions with
high affinity [4, 5]. Amino acids containing electron donors
include aspartate, glutamate, cysteine or histidine. Among
these, histidine is a ubiquitous amino acid usually present in
the metal-binding regions of metalloenzymes [6, 7]. Three-
dimensional (3D) structure analysis of many metalloproteins
revealed that histidine side chains usually folded into a
favourable conformation of stable metal-binding pockets [8].
Although histidine may also be present on the exposed surface
of many non-modified proteins, the consecutive 6–8 histidine
residues automatically fold into appropriate conformation with
extremely high affinity for nickel or cobalt ions compared to
the single exposed histidine residue. As a result, poly-histidine
residue has been one of the most widely used functional
tags in molecular cloning and protein chemistry. Besides,
only a few proteins in the nature have a native consecutive 6
histidine domain in their structures [9]. These advantages not
only enable specific isolation of the desired peptides tagged
with genetically engineered 6-histidine through a metal ion
column chromatography, but also may potentially assist protein
immobilization on a solid-phase support with the correct
orientation for future molecule–molecule interaction based
diagnostic detections or therapeutic applications [10–13].
Nitrilotriacetic acid (NTA) is a tricarboxylic acid
monoamino chelator that could form a stable complex with
transition metal ions such as Ni2+, Zn2+ and Co2+ [14]. In
the 3D structural conformation, two vacant coordination sites
on the metal ion are exposed, which enable stable and strong
interaction with the electron-donor containing pouch in the
poly-histidine sequences [8]. Of the metal ions, Ni2+ is
recognized to be the best one in most applications, although
recent studies have reported that the cobalt ion provides
improved specificity for the 6-His tagged peptides compared
to the nickel ion [15]. The correct orientation of biomolecules
and the preservation of their functionality have been one of the
most critical challenges for the development of nanoparticle-
based biomedical applications [10, 11, 16–19]. An antibody
or ligand library may thus take advantage of a self-assembly
monolayer (SAM) on the particle’s surface to enhance their
overall performance and ease of practical usage and storage.
Interestingly, there is no report on the direct synthesis of
nanoscale aqueous Fe3O4-NTA–Ni particles targeting His-
tagged proteins so far.
Recently, we synthesized Fe3O4–NH+3 nanoparticles with
an average diameter of 6.2 ± 1.1 nm and demonstrated
that their trypsin conjugates preserved functional activity
well [20, 21]. The aqueous Fe3O4–NH+3 nanoparticles also
displayed excellent in vitro biocompatibility and significantly
reduced water proton relaxation times for both T1 and T2.
Significantly reduced T2 and T ∗2 -weighted signal intensity were
observed in a 1.5 T clinical magnetic resonance (MR) imager
using phantom arrays. A fast response and prolonged inverse
contrast effect lasting for more than 1 week was observed in
T ∗2 -weighted MRI sequence of the liver of the test animal.
In this study, we provide a comprehensive and straight-
forward approach for the totally aqueous phase synthesis
of Nα,Nα-Bis(carboxymethyl)-L-lysine (nitrilotriacetic acid;
NTA) surface modified superparamagnetic Fe3O4 nanoparti-
cles (scheme 1). Their efficiency and specificity in protein pu-
rification were evaluated. Hexahistidine-engineered RGD4C
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peptide was synthesized to evaluate the efficiency of the selec-
tive targeting of cancer cells expressing αvβ3 and αvβ5 inte-
grin, compared to the identical nanoparticles modified by ran-
dom chemical crosslinking (scheme 1). The hemolysis assay
was performed using human whole blood as an initial step to
validate their potential future in vivo applications as molecular
imaging agents or targeted hyperthermia and/or chemothera-
peutic agents.
2. Experimental section
2.1. Chemicals and characterization
Bromoacetic acid and N ε-benzyloxycarbonyl-L-lysine were
purchased from Fluka; 10% Pd/C was purchased from
Lancaster; Coomassie Brilliant Blue G-250 was purchased
from Bio-Rad Laboratories Inc.; PVDF membranes were
purchased from PerkinElmer Inc., Boston, MA, USA; the
Renaissance Western Blot Chemiluminescence Reagents were
purchased from PerkinElmer Inc., Boston, MA, USA; the
Scientific Imaging films were purchased from Eastman Kodak,
Rochester, NY, USA; 1H, 13C NMR spectra were obtained on a
300 MHz Bruker Avance300. The thermogravimetric analysis
(TGA) was obtained on a Shimadzu PA-50WSI analyser. The
spectrophotometric measurements of proteins were obtained
on a Dynex Technologies MRX II. The spectrophotometric
measurements of hemocompatibility were obtained on a
Coulter Gen-S analyser.
2.2. Fe3O4–NH+3 nanoparticle preparation
For preparing water-soluble and dispersed Fe3O4 nanoparti-
cles, two-stage additions of protective agent and chemical co-
precipitation were employed in the process [20, 21]. The
1 M ferric chloride hexahydrate (FeCl3·6H2O > 99%) and
2 M ferrous chloride tetrahydrate (FeCl2·4H2O > 99%) were
prepared by dissolving iron salts in 2 M HCl solutions, re-
spectively. Two solutions containing FeII and FeIII at a pre-
determined mole ratio (FeIII/FeII = 2) were mixed, followed
by the addition of organic acid as adherent. Subsequently, the
pH of the solution was carefully adjusted to over 10 and an ap-
propriate amount of adherent was added to achieve complete
coating of the particle surface with the –NH+3 group, result-
ing in the Fe3O4 nanoparticle dispersion appearing as a black
colour.
2.3. Synthesis of Nα,Nα- Bis(carboxymethyl)-N ε-
(benzyloxycarbonyl)-L-lysine (N ε-Z-NTA)
Bromoacetic acid (0.52 g, 3.75 mmol) was dissolved in NaOH
solution (3 ml, 5N) and cooled at 0 ◦C. N ε-benzyloxycarbonyl-
L-lysine (0.42 g, 1.5 mmol) in 5 N NaOH solution (3 ml)
added dropwise at 0 ◦C while stirring [22]. After 2 h,
the ice bath was removed and the mixture was refluxed
overnight. The temperature of the mixture was cooled down,
followed by adding a 5 N HCl solution (6 ml) with additional
0.5 h stir. The product was collected by filtration and
washed by a 1 N HCl solution. Nα,Nα-Bis(carboxymethyl)-
N ε-(benzyloxycarbonyl)-L-lysine (N ε-Z-NTA, 0.44 g) was
obtained as a white solid with a yield of 78%. 1H-NMR
was performed with the following characteristics: (300 MHz,
d6-DMSO) δ = 1.2–1.8 (m, 6H, CHCH2CH2CH2CH2NH),
δ = 2.9 (q, 2H, J = 5.9 Hz, NHCH2CH2), δ = 3.3 (t,
1H, J = 7.2 Hz, NCHCH2), δ = 3.48 (dd, 4H, J = 21.9,
23.3 Hz, NCH2COOH), δ = 4.9 (s, 2H, C6H5CH2), δ = 7.2
(t, 1H, J = 5.4 Hz, OCONH), δ = 7.3 (m, 5H, C6H5CH2);
13C-NMR (75 MHz, d6-DMSO) δ = 173.5 (CHCOOH),
δ = 172.8 (CH2COOH), δ = 156.1 (OCONH), δ = 137.3
(phenyl-C1), δ = 128.4 (phenyl-C2, C3), δ = 127.8 (phenyl-
C4) δ = 65.1 (NCH2COOH), δ = 64.5 (NCHCOOH),
δ = 53.4 (OCONHCH2), δ = 29.2 (NCHCH2), δ = 29.1
(NHCH2CH2), δ = 23.0 (NCHCH2CH2CH2CH2NH).
2.4. Synthesis of Nα,Nα-Bis(carboxymethyl)-L-lysine(NTA)
Nα,Nα-Bis(carboxymethyl)-N ε-(benzyloxycarbonyl)-L-lysine
(1.09 g, 2.75 mmol) was dissolved in MeOH/H2O solution
(MeOH/H2O = 20/1, 40 ml) [22]. After the addition of
a spatula tip of Pd/C (10%), the mixture was hydrogenated
at room temperature. The reaction was completed after 3 h,
as monitored by TLC (MeCN/H2O = 4/1) and visualized
with UV and I2. The catalyst was filtered off and the product
was crystallized at 0 ◦C within 2 days. The crystals (0.617 g)
were collected and dried in vacuum. The final yield was cal-
culated to be 85%. 1H-NMR was performed with the fol-
lowing characteristics: (300 MHz, D2O) δ = 1.3–2.0 (m,
6 H, H2NCH2CH2CH2CH2CH), δ = 2.9 (t, 2H, NCHCH2),
δ = 3.8 (s, 4H, HCNCH2COOH); 13C-NMR (75 MHz,
D2O) δ = 171.5 (NCHCOOH), δ = 169.7 (NCH2COOH),
δ = 67.2 (NCH2COOH), δ = 54.7 (NCHCH2), δ =
38.6 (H2NCH2CH2), δ = 26.0 (NCHCH2), δ = 25.9
(NHCH2CH2), δ = 22.5(NCHCH2CH2CH2CH2NH).
2.5. Fe3O4 nanoparticles conjugated with NTA and Ni2+ ions
One millilitre of 0.1 µM (particle concentration) Fe3O4
nanoparticles with –NH3 modification was added to 1 ml of
0.2 M Nα,Nα-Bis(carboxymethyl)-L-lysine (NTA) and 400 µl
of 55% (w/w) glutaraldehyde at room temperature for stirring
for 8 h. After conjugating Fe3O4 nanoparticles with NTA, 2 ml
of 1.0 M NiSO4 was added and the mixture was stirred at room
temperature for different time periods. When the incubation
was completed, the mixture was centrifuged at 13 000 rpm
for 5 min and the supernatant was removed. The resulting
precipitates (Fe3O4-NTA–Ni) were redispersed in 2 ml H2O
and centrifuged at 13 000 rpm for 5 min to remove the excess
Ni2+ ions. The Fe3O4-NTA–Ni nanoparticles were further
redispersed in 1 ml H2O and analysed by atomic absorption
spectroscopy (AA) to measure the ratio of Ni2+ ion to Fe3O4-
NTA nanoparticles as a function of incubation period between
NiSO4 and NTA-Fe3O4.
2.6. The quantity of NTA molecules on Fe3O4 nanoparticles
The quantity of NTA molecules on the Fe3O4 nanoparticle’s
surface was measured and evaluated by thermogravimetric
analysis (TGA). The experiments were carried out using
14.79 mg of Fe3O4-NTA sample, which was placed in an open
Pt pan. Compressed air flowing at a rate of 20 ml min−1
served as the purge gas and the sample temperature was raised
from 26.8 to 600 ◦C at a rate of 10 ◦C min−1. Based on the
loss of sample weight, we can calculate the quantity of NTA
molecules conjugated with the Fe3O4 nanoparticles.
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2.7. Determination of the binding capacity for 6-His tagged
proteins
The binding capacity of the newly synthesized Fe3O4-NTA–
Ni nanoparticles to 6-His tagged proteins was evaluated by
using purified V344A mutant streptopain (MW 42 kDa) with
6-His tag on the N-terminus [23]. For the protein binding
assay, the purified streptopain solutions (350.86 µg ml−1)
varied from 0 to 390 µl were mixed with 10 µl of Fe3O4-
NTA–Ni nanoparticles (32 mg ml−1), then added to the binding
buffer to a total volume of 400 µl. Subsequently, the reaction
mixtures were incubated at 4 ◦C for 20 min. The nanoparticles
with adsorbed streptopain were isolated by a small magnet.
The nanoparticles were washed with 100 µl wash buffer
(200 mM NaH2PO4, 500 mM NaCl, pH 7.4) to eliminate
non-specific bindings. The flow-through solution and washing
solutions were collected to detect the non-binding proteins and
to calculate the quantity of the binding proteins on Fe3O4-
NTA–Ni. For the quantification of the purified streptopain,
Coomassie Brilliant Blue G-250 (Bio-Rad Laboratories Inc.)
was applied as the dye to visualize the proteins. The binding
capacity was determined by spectrophotometric measurement
of the optical adsorption (590 nm) of each fraction of the
collected solutions and converted into protein concentrations
according to the standard curve using BSA as the reference
protein.
The effect of elution buffers to the final yield of
protein purification was evaluated as a function of imidazole
concentration. The protein binding and wash procedure
were performed as the aforementioned text except for the
ingredients of the final elution buffers, which contained
different concentrations of imidazole. The final yield of the
target protein was evaluated by spectrophotometric analysis at
590 nm.
2.8. Purification of 6-His tagged recombinant proteins from
bacteria lysate
The E. coli BL21 (DE3) transfected with pET21a containing a
full-length mutant streptopain cDNA V334A with 6-his tagged
on the N-terminal end [23]. Cells were grown at 37 ◦C for 6–
8 h in LB medium (1 l of 10 g of Bacto-Trypton, 5 g of Bacto-
yeast extract, and 10 g of NaCl adjusted to pH 7.2 with 3N
NaOH). A final bacteria concentration at A600 = 0.5–1.0 was
used to induce recombinant gene expression by the addition
of isopropyl-1-thio-β-D-glactopyranoside (IPTG) to a final
concentration of 1 mM and further incubated for additional
24 h at 37 ◦C. The bacteria was collected by centrifugation
and lysed by liquid shear with a French press to obtain the final
lysate on ice, and then the lysate was centrifuged (13 000 rpm,
for 10 min at 4 ◦C) to remove the crude precipitates before
being subject to further protein purification.
To evaluate the efficiency of protein purification utilizing
newly synthesized NTA–Ni modified magnetite nanoparticles
through magnetic force manipulation, the supernatant of cell
lysate was mixed with a buffer solution containing the Fe3O4-
NTA–Ni nanoparticles at a concentration of 32 mg ml−1
followed by a magnetic separation. The protein purification
was performed as described earlier. The derived proteins
in each fraction were visualized on a SDS-PAGE after
electrophoresis and Coomassie Brilliant Blue G-250 staining.
2.9. Western blot analysis
To evaluate the specificity and degradation in the elution
process of the target protein, Western blot analysis was
performed. 20 µl of each collected fraction was loaded
on a 15% SDS-polyacrylamide gel and separated by
electrophoresis, then transferred to a PVDF membrane
(PerkinElmer Inc., Boston, MA, USA). The streptopain was
detected with a horse radish peroxidase conjugated monoclonal
antibody against 6-His-tag of the fusion protein (Chemicon
International Inc., Temecular, CA, USA). After incubation,
the signal was detected by chemiluminescence assay using
the Renaissance Western Blot Chemiluminescence Reagent
(PerkinElmer, Inc., Boston, MA, USA) and Scientific Imaging
film (Eastman Kodak, Rochester, NY, USA).
2.10. Hemocompatibility of Fe3O4-NTA–Ni nanoparticles
Spectrophotometric measurement for the presence of
hemoglobin in human plasma released from ruptured red blood
cells after exposure to the nanoparticles served as an index for
their hemocompatibility. The fresh human whole blood was
obtained from a healthy donor with informed consent, follow-
ing guidelines for studies using human tissues. Fe3O4-NTA–Ni
nanoparticles were added to 1 ml of human whole blood con-
taining 12 IU sodium heparin to final particle concentrations of
0, 10−10, 10−9, 10−8, 10−7, 10−6, and 10−5 M. The solutions
were gently mixed on a rotary shaker for 4 h at 37 ◦C followed
by centrifugation at 1200 rpm for 10 min to remove the red
blood cells and another centrifugation at 13000 rpm for 30 min
to eliminate the nanoparticles. The hemoglobin concentration
in the supernatant was then determined by spectrophotometric
analysis (454/528 nm) in a Coulter Gen-S analyser (Beckman
Inc, USA).
As a comparative study, we also evaluated the relative
hemolysis of the nanoparticles at different concentrations
compared to the positive and the negative control. Fresh human
blood was collected and diluted with normal saline solution
(8 ml blood + 10 ml normal saline). The hemolysis assay
was performed by adding 20 µl of the diluted blood to 1 ml of
0.1% sodium carbonate solution as a positive control or 1 ml of
normal saline as a negative control or 1 ml of the experimental
groups containing different concentrations of the nanoparticles,
ranging from 10−6–10−10 M. After incubation, all the test tubes
were centrifuged for 5 min at 3000 rpm and the supernatant
was transferred to a cuvette for spectroscopic analysis at a
wavelength of 545 nm, and the percentage of hemolysis was
calculated by:
Percentage hemolysis
= [OD(test) − OD(negative control) × 100]/
[OD (positive control) − OD (negative control)]
where OD = the optical density at 545 nm.
The percentage of hemolysis was calculated based on
the average of three replicates. High hemocompatibility was
given for samples with <5% hemolysis, hemocompatible for
samples within 10% hemolysis, and non-hemocompatible for
>20% hemolysis.
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Scheme 2. The surface modification of the Fe3O4-NTA–Ni nanoparticle complex. A covalent bond is established between the primary amine
of the nanoparticle surface and glutaraldehyde. The NTA covalently attaches onto the nanoparticle with a projected carboxyl group to chelate
the nickel ion and leaves two vacant sites for affinity binding to 6-His tagged proteins.
2.11. Preparation of RGD-4C-6-His magnetite nanoparticle
conjugate and in vitro targeting analysis
The RGD-4C-6-His peptide (H-Ala-Cys-Asp-Cys-Arg-Gly-
Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Gly-Gly-His-His-His-
His-His-His-OH, disulfide bridge: 2–10 and 4–8) was synthe-
sized (Genesis Biotech Inc., Taiwan) for the evaluation of cell
targeting. The resulting Fe3O4-NTA–Ni reserves two binding
sites for the interaction with the poly-histidine structure of the
fusion peptide (scheme 2). Two vacant coordination sites on
the nickel ions enable strong complexing with the electron-
donor containing pouch in the poly-histidine sequences. For
conjugation of the RGD-4C-6-His peptide to the nanoparticle
surface, the peptide was incubated with the particle at room
temperature for 5 min under gentle agitation in a 10:1 peptide-
to-nanoparticle molar ratio, then subjected to magnetic sepa-
ration and washing to remove non-binding peptides. The par-
ticles were re-suspended in phosphate buffer containing 10%
goat serum and sonication in a water bath for 10 min before
the experimental targeting. Oral cancer cell line HCDB-1 [24],
which expresses a high level of αvβ3 integrin and normal oral
keratinocytes (HNOK) with lower expression level, served as
the model system and the negative control for a selective target-
ing experiment, respectively. The cells were grown in chamber
slides (Nalge Nunc International Corp., IL, USA) in their re-
spective culture media at 37 ◦C in humidified air containing
5% CO2. The RGD-4C-6-His magnetite nanoparticles were
then co-incubated with cells cultured on the chamber slides for
30 min at 4 ◦C with gentle shaking. The medium was removed
and washed twice with PBS, followed by fixing with 4% glu-
taldehyde. To visualize the nanoparticle aggregates caused by
affinity binding between RGD-4C and integrin on the target
cells, Pearl’s iron staining was performed and the results were
photographed under an optical microscopy (Olympus, BH-2).
2.12. Instrumentation
Electron micrographs of the Fe3O4 dispersions were carried
out using a drop of the sample onto a copper mesh
coated with an amorphous carbon film, and then dried in a
vacuum desiccator. The prepared samples were studied in
a transmission electron microscope (JEOL JEM-1200-EX).
Thermogravimetric analysis was carried out under a stream
of nitrogen, at a heating rate of 10 ◦C min−1, using a TA Q50
Thermogravimetric analyser (TA Instruments Inc.).
50 nm
Figure 1. TEM image of Fe3O4 nanoparticles conjugated with NTA.
3. Results and discussion
3.1. Preparation of Fe3O4–NH+3 modified with NTA and Ni2+
ion
We have recently reported the aqueous synthesis of Fe3O4–
NH+3 nanoparticles (6.2 ± 1.1 nm) and applied enzyme
bio-conjugation, such as trypsin [20, 21]. This strategy
for enzyme immobilization could preserve the enzyme
activity. Furthermore, we demonstrated the negative
contrast effect for MR imaging applications and their
biocompatibility [21]. Herein, the Fe3O4 nanoparticle surface
with amine functional groups is further covalently crosslinked
to NTA by glutaraldehyde (scheme 2).
Scheme 2 illustrates the surface chemistry of the
newly synthesized nanoparticles. The NTA was covalently
attached to the amino groups on the nanoparticles by using
glutaraldehyde as the linker. Figure 1 displays the TEM image
of as-prepared Fe3O4-NTA nanoparticles with some degree of
aggregation. The nickel ions were chelated by NTA molecules
immobilized on the nanoparticle surface. The resulting Fe3O4-
NTA–Ni reserves two binding sites for the interaction with
the poly-histidine structure of the fusion peptide (scheme 2),
where two vacant coordination sites on the nickel ions are
exposed and enable strong coordination with the electron-
donor containing pouch in the poly-histidine sequences.
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Figure 2. The thermogravimetric analysis (TGA) curve for
Fe3O4-NTA (inset: TGA behaviour from pure NTA molecules).
TGA analysis was carried out and the quantity of the
NTA conjugation was evaluated from the weight lost in the
TGA curve. The TGA profile shows that the weight loss
occurs in steps, with total loss of 26% up to 600 ◦C (figure 2).
The initial weight loss of ∼6.5% can be attributed to the
elimination of physical and chemical adsorbed H2O between
30 and 160 ◦C. The weight loss of ∼4.7% in the temperature
range 160–210 ◦C is assigned as the decomposition of the
linker, glutaraldehyde. The glutaraldehyde molecules have
been found to decompose at a temperature of ∼188 ◦C [25].
A pronounced weight loss step is found in the temperature
range from 210 ◦C up to 600 ◦C, which can be ascribed to the
decomposition of the NTA molecules and is consistent with the
TGA behavior of the pure NTA molecules (inset in figure 2).
It is evaluated that a weight loss of ∼14.8% is determined
and approximately 340 NTA molecules are tagged on a Fe3O4
nanoparticle.
The adsorption of Ni2+ onto Fe3O4-NTA was monitored
as a function of incubation time. The ratio of Ni2+ and Fe3O4
was calculated based on the analysis of atomic absorption.
Adsorption studies of nickel ions indicate that the ratio of Ni2+
binding on the Fe3O4-NTA nanoparticles rapidly increased
from 0 to 80 over the initial incubation time of 2 h. Then the
adsorption ratio gradually rose to ∼140 when the incubation
was extended for 8 h (figure 3). After incubation for 10 h,
the intensity increased only slightly to ∼154, which suggests
that the binding capacity of Fe3O4-NTA should have reached
saturation for the nickel ions.
3.2. Purification of 6-His tagged recombinant proteins from
bacteria lysate
The binding capacity of the Fe3O4-NTA–Ni to 6-His tagged
proteins was evaluated by using purified recombinant 6-His
Figure 3. Adsorption of nickel ions onto the Fe3O4-NTA
nanoparticles as a function of incubation time between NiSO4 and
Fe3O4-NTA.
Figure 4. The ratio of protein to Fe3O4-NTA–Ni nanoparticles as a
function of protein dosage. The total amount of the nanoparticles
remained constant throughout the experiments (32 mg−1ml−1 for
Fe3O4-NTA–Ni).
tagged V344A mutant streptopain (42 kDa). Figure 4 shows
that the protein binding efficiency gradually increased from
the initial 0.01 to 0.23 (mg protein per mg Fe3O4-NTA–
Ni). In these results, we found that the binding capacity of
Fe3O4-NTA–Ni nanoparticles is about 45 times higher than
that of the commercial magnetic microbeads (Dynabead®,
5–12 µg protein per mg bead), which indicates that the
high surface/volume ratio of the nanoparticles may contribute
to the higher efficiency. The optimal performance of the
protein release was investigated by modulation of imidazole
concentration in elution buffer. As shown in figure 5, the eluted
efficiency reaches a plateau as the imidazole concentration
approaches 300 mM. When the imidazole concentration in the
elution buffer is higher than 500 mM, the excess imidozole
would interfere with the spectrophotometric analysis of the
protein. Thereafter, a 400 mM of imidazole concentration is
chosen for the following protein purification.
As the synthesized Fe3O4-NTA–Ni nanoparticles are able
to bind and release purified 6-His-tagged peptides, we further
evaluate the direct protein purification from bacteria expressing
mutant streptopain with 6-His tagged on the N-terminus. The
process is illustrated in scheme 1. Figure 6(a) shows the
SDS-PAGE analysis of the products from each fraction of the
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Figure 5. The 6-His protein desorption as a function of imidazole
concentration.
a b
Figure 6. (a) SDS-PAGE analysis reveals a specific binding of the
Fe3O4-NTA–Ni nanoparticles to the streptopain mutant protein with
6-His tag from a crude bacteria lysate following magnetic force
separation. (b) Western blot analysis probed by anti-6-His
monoclonal antibody shows a specific high yield of the protein
following the magnetic purification protocol.
elution process. A prominent band at a molecular weight of
42 KDa (the molecular weight of streptopain) was observed in
the original bacteria total lysate (lane 1), and the first (lane 4)
and second elusion (lane 5), but was not detectable in the
pass through (lane 2) and wash buffer (lane 3) collections. In
Figure 7. (a) Hemocompatibility assay of the as-synthesized Fe3O4-NTA–Ni nanoparticles performed in freshly prepared human whole blood
by measuring the presence of hemoglobin in the serum derived from lysed red blood cells upon exposure to the nanoparticles. No significant
hemolysis activity is detected in all dosages compared to the control set of the phosphate buffer saline control (0.0 M particle concentration).
(b) The Fe3O4-NTA–Ni nanoparticles show no significant hemolysis detected during time periods of 1, 2 and 4 h of exposure in all test
dosages, with reference to the positive control (0.1% sodium carbonate).
addition, Western blot analysis also demonstrated a single band
with the correct molecular weight of the protein. Significant
protein recovery without evidence of degradation and non-
specific binding was observed (figure 6(b)). Furthermore,
thermal stability of the Fe3O4-NTA–Ni nanoparticles was
observed, as they can be stored at a temperature of 50 ◦C for
more than one month and still retain their functionality.
Since the presented iron oxide particles are fabricated in
an aqueous environment, a similar idea for modulated design
of SAM on nanoparticles such as conjugation of glutathione
for the purification of GST-fusion proteins could be achieved
and is currently under investigation.
3.3. The RGD-4C-6-His magnetite nanoparticle conjugate
and in vitro targeting analysis
The specific affinity between 6-His-tagged peptides and NTA–
Ni establishes a platform to engineer precisely the oriented
biomolecules on nanoparticle surfaces, where the conventional
chemical crosslinking strategies usually result in a randomized
orientation in biomolecules. This enables enhanced in
vivo targeting for the molecular diagnosis or therapeutic
applications.
For further in vitro or in vivo studies, a primary evaluation
of the hemocompatibility was conducted by hemolysis assay
for Fe3O4-NTA–Ni. The hemolysis assay shows no detectable
hemolysis activity of the nanoparticles at all dosages ranging
from 0.1 mM to 10 mM particle concentrations, as seen in
figure 7(a). In addition, the potential hemolysis behaviour
was compared to the positive (0.1% sodium carbonate) and
the negative control (normal saline) after incubation for 1, 2
and 4 h. As shown in figure 7(b), all test dosages present no
significant hemolysis (<1% of the control).
Cancer cells and their neoangiogenic blood vessels usually
present altered expression of cell adhesion molecules including
specific types of integrins [26]. Cyclic RGD-4C peptide
presents specific affinity to αvβ3 and α3β5 integrins that
often selectively express in tumor tissues. Enhanced tumor
gene therapy has been demonstrated using RGD-4C modified
adenovirus [27]. This peptide has also been applied for
the imaging and monitoring of tumor angiogenesis [28, 29].
Herein, we design a fusion peptide consisting of a cyclic
4180
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Figure 8. The RGD4C-6His cyclic peptides self-assembled on Fe3O4-NTA–Ni nanoparticles present no detectable binding to the normal oral
keratinocytes (a) compared to the oral cancer cell HCDB1 (b), as revealed by iron staining (blue colour). Fe3O4 nanoparticles with traditional
chemical crosslinking of the RGD4C-6His cyclic peptides (c) show significantly less efficient targeting than (b). Nanoparticles alone fail to
target HCDB1 cells and present only background staining (d). (Scale bar = 20 µm.)
RGD-4C domain, a 6 glycine spacer and a 6-His tag on
the C-terminal end. Oral cancer cells (HCDB-1) [24]
expressing a high level of αvβ3 integrin compared to the
normal oral keratinocytes (HNOK) are used for the in vitro
targeting. Nanoparticles were incubated with the peptides
before incubation with either fixed or living cells cultured on
a chamber slide. The results show a prominent selectively
targeting of the nanoparticle-RGD-4C-6-His complex to the
cancer cells (figure 8(b)), while only little non-specific staining
was detectable in the normal keratinocytes (figure 8(a)).
In a control experiment without molecular orientation, we
synthesized RGD-4C surface modified nanoparticles using a
simply applied chemical crosslinking method using 1-ethyl-
3-(3-dimethylaminopropyl)-carbodiimide (EDC) to form a
covalent bond between the amine group on the nanoparticle
surface and the carboxyl group on the peptide. As shown
in figure 8(c), the randomly crosslinking RGD-4C without
molecular orientation revealed significantly less efficient
targeting than the self-assembled RGD-4C-nanoparticles in
figure 8(b). Finally, figure 8(d) shows that nanoparticles alone
failed to target HCDB1 cells and showed only background
staining. These results suggest the advantage of the self-
assembly strategy through the ‘key’ (NTA-Ni) to ‘key lock’ (6-
His tag on the targeting biomolecule warhead) concept, which
provides enhanced targeting efficiency due to the precisely
controlled biomolecular orientation on the nanoparticle.
4. Conclusions
We have demonstrated the aqueous synthesis of Fe3O4–NH+3
nanoparticles modified with NTA-Ni. The modified
nanoparticles show high efficiency and specificity for the
rapid purification of 6-His tagged proteins and present no
hemolysis between concentrations of 10−5–10−10 M as well
as satisfactory biocompatibility for in vitro studies. In vivo
targeting assay showed significantly enhanced tumor cell
targeting compared to random chemical conjugation. These
results indicate that the as-synthesized iron oxide nanoparticles
may hold great potential as universal modularly designed
functionalized carriers for magnetite field guided biomolecule
purification, magnetic force driven drug delivery nanovehicles,
and molecular imaging agents, which present the advantages
of modularly designed particle and targeting moiety with
guaranteed biomolecule orientation. The platform could be
applied further to a broad spectrum of affinity-based protein–
protein interaction biosensing.
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